1LLY:BIT
Eli Lilly and Company
1.044,80 €
arrow_upward
+0,02%(+0,20) 1D
29. sep., 13:18:32 GMT +2 · EUR
search
Vsi simboli
1D
5D
1M
6M
TLDD
1L
5L
MAKS
| Simbol | Cena | Sprememba | Odstotna sprememba |
|---|
insights_autoGeneriranje najpomembnejših vpogledov za 1LLY …
Odpri
1.047,20 €
Visoka
1.050,60 €
Nizka
1.044,80 €
Tržna kapitalizacija
1,12 bil.
Povprečni promet
346,00
Promet
163,00
52-tedenski najvišji tečaj
1.106,80 €
52-tedenski najnižji tečaj
610,00 €
Št. zaposlenih
50 tis.
Odpri
1.047,20 €
Visoka
1.050,60 €
Nizka
1.044,80 €
Tržna kapitalizacija
1,12 bil.
Povprečni promet
346,00
Promet
163,00
52-tedenski najvišji tečaj
1.106,80 €
52-tedenski najnižji tečaj
610,00 €
Št. zaposlenih
50 tis.
Novice
Iz spletnih virov in novičarskih partnerjev
Investing.com Canada
·
pred 43 minutami
Lilly’s Zepbound shows greater weight loss than Wegovy HD By Investing.com
Stock Titan
·
pred 53 minutami
An indirect comparison found over 3 times the odds of losing 20% of body weight on Lilly's drug versus Wegovy
Yahoo Finance
·
pred 1 uro
Lilly touts Foundayo advantage over Novo's Ozempic pill in diabetes analysis
MedWatch
·
pred 1 uro
Eli Lilly targets larger deals to build business beyond obesity drugs
Profil
Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named.
The company is ranked 4th on the list of largest biomedical companies by revenue and is the most valuable pharmaceutical company worldwide. It is ranked 100th on the Fortune 500 and 138th on the Forbes Global 2000. In November 2025, the company reached a $1 trillion market capitalization, the first health-care company in the world to do so.
The company's primary products are tirzepatide for the treatment of type 2 diabetes, weight loss, and obstructive sleep apnea; abemaciclib for the treatment of advanced or metastatic breast cancers; dulaglutide for the treatment of type 2 diabetes; ixekizumab for the treatment of autoimmune diseases; and empagliflozin for the treatment of type 2 diabetes. Wikipedia
Vizitka: Eli Lilly and Company
Generalni direktorDavid A. Ricks
Št. zaposlenih50 tis.
Ustanovljeno1876
SedežIndianapolis, Indiana, Združene države Amerike
Sektor-
Spletno mestolilly.com